HomeClene (CLNN) CEO On Biopharmaceutical Company & Earnings Beat
Clene (CLNN) CEO On Biopharmaceutical Company & Earnings Beat

Clene (CLNN) stock was up around 3% today. Recent earnings report indicated $0.42 in EPS and $110K in revenue, beating estimates. CEO, Rob Etherington, says that the biopharmaceutical company focuses on neurodegenerative diseases. What are the plans for the company's future growth, and how will the CLNN stock price continue to perform?

The Watch List

18 Nov 2021

ON AIR
3:00 am
Trading 360
replay
12:00 am
Fast Market
REPLAY
education
1:00 am
Your First Trade
REPLAY
1:30 am
Next Gen Investing
REPLAY
education
2:30 am
Your First Trade
REPLAY
ON AIR
3:00 am
Trading 360
REPLAY
4:00 am
Fast Market
REPLAY
5:00 am
Next Gen Investing
REPLAY
education
6:00 am
Your First Trade
REPLAY
6:30 am
Trading 360
REPLAY
7:30 am
Fast Market
REPLAY
8:30 am
Next Gen Investing
REPLAY
education
9:30 am
Your First Trade
REPLAY
10:00 am
Trading 360
REPLAY
11:00 am
Fast Market
REPLAY
12:00 pm
Next Gen Investing
REPLAY
education
1:00 pm
Your First Trade
REPLAY
1:30 pm
Trading 360
REPLAY
2:30 pm
Fast Market
REPLAY
3:30 pm
Next Gen Investing
REPLAY
education
4:30 pm
Your First Trade
REPLAY
5:00 pm
Trading 360
REPLAY
6:00 pm
Fast Market
REPLAY
7:00 pm
Next Gen Investing
REPLAY
education
8:00 pm
Your First Trade
REPLAY
8:30 pm
Trading 360
REPLAY
9:30 pm
Fast Market
REPLAY
10:30 pm
Next Gen Investing
REPLAY
education
11:30 pm
Your First Trade
REPLAY

Get Market Minute

Daily insights for every investor

FOLLOW US